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Abstract Paliperidone was formulated in mucoadhesive
nanoemulsion with the aim of improving its solubility and
transnasal delivery, which can further utilized for its pre-
clinical evaluation. Solubility of Paliperidone in oils,
emulsifiers, co-emulsifiers was determined to identify
nanoemulsion components. Emulsifier and co-emulsifiers
were screened for their ability to emulsify selected oily
phase. Phase diagrams were constructed to identify the area
of nanoemulsification. Paliperidone nanoemulsion was
formulated using spontaneous nanoemulsification method.
The three nanoemulsions (PMNE4, PMNE5, and PMNE6)
containing 5.71–6.80 % oleic acid as an oily phase,
47.62–51.63 % labrasol and plurol oleique CC 497 as
emulsifier mixture (1:1), 42.86–45.58 % (wt/wt) aqueous
phase having a suitable optical transparency of
98.33–99.33 %, globule size of 28.8–43.2 nm and poly-
dispersity of 0.129–0.152 were selected for the incorpora-
tion of mucoadhesive polymer. The PMNE6 showed
highest flux (5.072 ± 0.13 lg/cm2/min) with enhancement
ratio of 1.1 as compared to Paliperidone solution (PS). The
diffusion co-efficient of PMNE6 was significantly higher
than PMNE5, PMNE4 and PS and followed higuchi model.
The formulation was found to be free from nasal cilio
toxicity. All formulations were found to be stable for
6 months at room temperature.
Keywords Ex vivo permeation study  Nanoemulsion 
Nasal cilio toxicity study  Paliperidone
Introduction
Schizophrenia is one of the psychotic mental disorders and
affects an individual’s thoughts, behaviors, and social
functioning. The major problem in treating mental disorders
is due to the inability of the therapeutic agents to surpass the
blood brain barrier (BBB) and the blood cerebrospinal fluid
barrier. One of the possibilities to overcome this barrier is
drug delivery to brain using novel drug delivery systems like
nanoemulsions exploring nanotechnology (Canuso et al.
2008; Patel et al. 2010, 2013a , b, 2014).
Paliperidone (PALI) is an atypical antipsychotic agent
that belongs to the class of benz-isoxazole and approved
for the treatment of schizophrenia (Canuso et al. 2008;
Patel et al. 2010, 2013a, b, 2014). It is a lipophilic drug
having oral bioavailabity of 28 %. This is primarily
attributed to its poor aqueous solubility, and high
lipophilicity and extensive first pass metabolism. Consid-
ering the limitations, a strategy which will increase PALI
solubility, reduce its first pass metabolism and overcome
BBB through delivering PALI directly to the target site is
highly desirable. The utility of nanoemulsions (NEs) has
been successfully established in optimizing the therapeutic
performance of many lipophilic drugs. Recently, increasing
attention has been focused on nanoemulsion based drug
delivery due to their ease of preparation with biocompati-
ble formulation components, unique properties such as
smaller droplet size (50–200 nm), increased drug solubil-
ity, and improved mucosal permeation, which further jus-
tifies rational of this study.
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An alternative route, intranasal drug delivery system has
now been recognized as a reliable route for the administra-
tion of drugs next to parenteral and oral routes. The olfactory
region of the nasal mucosa provides a direct connection
between the nose and the brain. The advantages of nasal
route are rapid absorption; higher bioavailability reduced
first pass metabolism, non-invasive administration, and self-
medication as well as improved patient compliance (Canuso
et al. 2008; Patel et al. 2013a, b, 2014). It is also reported in
our earlier studies that absorption of PALI through transnasal
route was more efficient when given in an oil based formu-
lation (microemulsion) (Patel et al. 2013a, b). These studies
outcomes render PALI as a potent candidate for lipid based
systems such as nanoemulsion for intranasal delivery.
However, these formulations may suffer from drawbacks
such as rapid nasal mucocilliary clearance of PALI. To get
the better of this, many research groups have demonstrated
the use of a potent mucoadhesive systemwhich improves the
nasal residential time and prolongs the intimate contact of
drug with nasal mucosa with improved absorption.
Taken together, this information has led our research
group to a formulated mucoadhesive nanoemulsion of
PALI with the aim of improving its solubility and trans-
nasal delivery. This paper describes the formulation and
in vitro/ex vivo evaluation of nanoemulsion based intra-
nasal drug delivery system containing paliperidone.
Materials and methods
Materials
Paliperidone pure powder was obtained as a gift sample from
Torrent pharmaceutical Ltd. (Ahmedabad, India). Labrafil M
1944, labrafac CC, labrasol, plurol oleique CC 497, and lau-
roglycol 90, (Gattefosse Saint-Priest, France) were procured
as gratis samples. Polycarbophil AA-1, (pharmagrade,
molecular weight approximately 3.5 million) was procured as
gratis sample fromLubrizol AdvancedMaterial India Pvt Ltd.
(Mumbai, India). Oleic acid, tween 80, potassium dihydrogen
phosphate, methanol and propylene glycol were purchased
from Suvidhinath Laboratories (Vadodara, Gujarat). Double
distilled water was used throughout the study. All other
chemicals and solvents were of analytical reagent grade, and
used as received without further purification.
Paliperidone nanoemulsion development
Solubility study
The solubility of PALI in various oils, emulsifiers, co-
emulsifiers was determined by a shake flask method. Briefly,
an excess quantity of PALI was added in each stoppered
glass vial containing 2 ml of the selected oils, emulsifiers and
co-emulsifiers, and mixed using cyclomixer. The vials were
then incubated at 37 ± 1.0 C in an isothermal shaker for
72 h. The samples were centrifuged at 3000 rpm for 15 min
and subsequently filtered through 0.22 lm membrane filter.
The filtrate was assayed by HPTLC method to estimate the
amount of drug solubilized. All measurements were done in
triplicate (Patel et al. 2010).
Construction of phase diagram
Phase diagram was constructed to define the extent and
nature of the NE regions. Phase diagrams were constructed
using spontaneous nanoemulsification method at an ambi-
ent temperature. For construction of phase diagram,
emulsifier was blended with co-emulsifier in fixed weight
ratios (Km, 1:1, 2:1 and 3:1 w/w). Each emulsifier and co-
emulsifier mixture (Emix) was then mixed with oil at
ambient temperature. For each phase diagram, the ratio of
oil to the Emix was varied as 9:1, 8:2, 7:3, 6:4, 5:5, 4:6,
3:7, 2:8, 1:9 (w/w). Water was added dropwise to each oil-
Emix mixture under vigorous stirring. After equilibrium,
the samples were visually checked and determined as being
clear/transparent (Elshafeey et al. 2009; Jogani et al. 2008;
Kumar et al. 2008; Patel et al. 2009, 2013a, b).
NE which shows phase separation was rejected. The
area of NE was identified for respective Km in which NE
with desired globule size and stability were obtained.
Preparation of nanoemulsion formulations
The PALI loaded NE (PNE) were prepared by the dissolving
PALI (5 mg/mL) in oil. Emulsifiers were weighed accu-
rately and mixed with oil to form homogenous isotropic
mixture. Required amount of water was added to the mixture
to obtain PNE. PALI loadedmucoadhesive NE (PMNE) was
prepared by the addition of polycarbophil AA-1 (0.50 %,
w/w) to PNE and the dispersion stirred for 1 h. The com-
position of PNE and PMNE is shown in Table 1.
Preparation of solution
The PS (5 mg/mL) meant for the comparative evaluation
was prepared by dissolving PALI (50 mg) in 10 mL of
propylene glycol (PG).
Evaluation of nanoemulsion
Globule size and zeta potential
The globule size and polydispersity index (PDI) of NE was
measured by photon correlation spectroscopy (PCS) with
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in-built Zetasizer (Nano ZS, Malvern Instruments, UK) at
633 nm. Helium–neon gas laser having intensity of 4 mW
was the light source. The globule size was calculated using
Stokes–Einstein relationship by Zetasizer Software. Elec-
trophoretic mobility (lm/s) was measured using small
volume disposable zeta cell and converted to zeta potential
by in-built software using Helmholtz–Smoluchowski
equation (Elshafeey et al. 2009; Jogani et al. 2008; Kumar
et al. 2008; Patel et al. 2009, 2013a, b).
Viscosity
The viscosity of NE was measured using a Brookfield
Viscometer LVDV-IIIU (Brookfield Engineering LABS,
Stoughton, MA) with spindle SC 18 at 8–30 rpm. All
aspects of testing were controlled using optional Rheocalc
Software (Patel et al. 2009).
Drug content
For determination of drug content, about 1 mL of the NE
was taken in a 10 mL volumetric flask and dissolved in
methanol. It was diluted appropriately and analyzed using
reported HTPLC method (Patel et al. 2010).
Further, prepared nanoemulsion formulations were char-
acterized by the measurement of pH, conductivity, percent-
age transmittance, and refractive index (Patel et al. 2009).
In vitro release studies
In vitro release study was conducted using a diffusion cell
(Orchid Scientifics, Nashik, India) with a diameter of
10 mm. The receiver chamber containing 20 mL diffusion
medium (phosphate buffer, pH 5.0) was kept at controlled
experimental temperature (37 ± 0.5 C). Diffusion med-
ium was continuously stirred using teflon coated magnetic
bar at a constant rate, in such a manner that surface of
dialysis membrane (Hi-media) was just rinsed by diffusion
medium. Samples from receiver compartment were with-
drawn at predetermined time interval for 4 h and analyzed
using HPTLC method (Patel et al. 2010).
Ex vivo permeation study
The freshly excised sheep nasal mucosa (from the slaughter
house), except the septum part, was kept in phosphate
buffer saline (PBS), pH 6.4 for 15 min to equilibrate. The
excised superior nasal membrane was then mounted on the
diffusion cell (diameter of 10 mm and mucosa thickness
0.2 ± 0.1 mm). The tissue was stabilized using phosphate
buffer (pH 5) in both the compartments and allowed to stir
for 15 min on a magnetic stirrer (Kumar et al. 2009; Lalani
et al. 2014; Patel et al. 2013a, b).
For ex vivo permeation study, each formulation (1 mL)
was placed in the donor compartment of the diffusion cell.
The temperature of the receiver chamber containing 20 mL
of diffusion media (phosphate buffer, pH 5.0) was con-
trolled at 37 ± 0.5 C. Samples from receiver compart-
ment were withdrawn at predetermined time interval for
4 h and analyzed using HPTLC method (Patel et al. 2010).
Different evaluation parameters such as % drug diffused,
flux, diffusion co-efficient and enhancement ratio (Er = -
PALI flux at steady state (Jss) of NE formulation/Jss of
control vehicle) were derived. The permeation kinetic of
PALI from each formulation was evaluated by fitting dif-
ferent kinetic models (Jogani et al. 2008; Kumar et al.
2008; Patel et al. 2009, 2013a, b).
Nasal cilio toxicity study
Histopathological studies were performed using sheep
nasal mucosa similarly that of ex vivo diffusion study, to
evaluate nasal toxicity of developed NE formulation. Three
sheep nasal mucosa pieces (P1, P2, P3) with uniform
thickness were selected and mounted on Franz diffusion
cells. P1 was treated with 0.5 mL of PBS (pH 6.4, negative
control), P2 with 0.5 mL of isopropyl alcohol (positive
control), and P3 was treated with PMNE6 for 1 h. After
1 h, the mucosa were rinsed with PBS (pH 6.4) and sub-
jected to histological studies and photographed by micro-
scope (Polarizing Microscope RPL-55 Series, Radical
Instruments, India) (Jogani et al. 2008; Kumar et al. 2008;
Patel et al. 2009, 2013a, b).
Table 1 The composition of the PALI loaded nanoemulsion and mucoadhesive nanoemulsion formulations
Ingredients (w/w) PNE1 PNE2 PNE3 PNE4a PNE5a PNE6a PNE7 PNE8 PNE9 PNE10
Oleic acid 2.38 2.08 1.85 1.70 1.56 1.43 1.75 2.05 2.4 2.3
Labrasol:plurol oleique cc 497 (3:1) 9.52 10.41 11.11 11.90 12.5 12.86 – – – –
Tween 80:propylene glycol (1:1) – – – – – – 15.73 16.39 16.82 16.85
Distilled water 13.10 12.5 12.04 11.39 10.93 10.71 7.52 6.56 5.77 5.34
Each formulation contains paliperidone 5 mg/mL
a PNE4, PNE5 and PNE 6 formulations additionally contain 0.5 %wt/wt of polycarbophil as mucoadhesive agent, and further referred as
PMNE4, PMNE5 and PMNE6 respectively
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Infrared study
The infrared (IR) spectra (between 4000 and 400 cm-1) of
PALI, plain NE, optimized PNE6 and PMNE6 were taken
using an IR spectrophotometer (Spectrum GX FT-IR,
Perkin Elmer, Norwalk, CT) to detect any possible inter-
action between the drug and excipients (Patel et al. 2009,
2015).
Stability study
Optimized formulations were subjected to stability studies
for a period of 6 months at room temperature. After
6 months of storage, the NE formulations were subjected to
test for physical stability via creaming, phase separation, or
flocculation via accelerated centrifugation cycle
(30009g for 15 min) and chemical stability via pH, drug
content (Azeem et al. 2009; Borhade et al. 2012; Patel et al.
2009).
Statistical analysis
All experiments were performed in triplicates. All data are
reported as mean ± standard deviation (SD) and the
groups were compared using ANOVA, with p\ 0.05
considered statistically significant.
Results and discussion
Screening of nanoemulsion components
The solubility of practically insoluble PALI was found
highest in the oleic acid (184.29 ± 2.00 mg/mL) and least
in labrafil M 1944 CS (3.14 ± 0.46 mg/mL). Further, it is
reported in the literature that oleic acid act as a lipophilic
permeation enhancer and can be useful to improve the
membrane permeability (Azeem et al. 2009; Patel et al.
2015; Pierre et al. 2006). Hence, oleic acid was selected as
the oily phase for the preparation of NE (Pierre et al. 2006).
An important criterion for selection of the emulsifiers is
that the required hydrophilic lipophilic balance (HLB)
value to form the oil–water NE be greater than 10. Emul-
sifiers play a major role in the formation and stabilization
of NEs. They prevent the coalescence of drops by reducing
the interfacial tension and by forming a stearic barrier
against globule coalescence. PALI has got highest solu-
bility in tween 80 (T-80) (HLB 15) and labrasol (HLB 14)
as compared to other emulsifiers. Therefore, T-80 and LAB
were chosen as an emulsifier for the preparation of NEs
(Azeem et al. 2009; Borhade et al. 2012; Patel et al. 2009).
Most single-chain emulsifiers do not lower the oil–water
interfacial tension sufficiently to form NEs and short to
medium chain length alcohols are necessary as co-emul-
sifiers. The co-emulsifier also ensures that the interfacial
film is flexible enough to deform readily around each
globule as their intercalation between the primary emulsi-
fier molecules decreases both the polar head group inter-
actions. Transient negative interfacial tension and fluid
interfacial film are rarely achieved by the use of single
emulsifier; usually, addition of a co-emulsifier is necessary.
The presence of co-emulsifier decreases the bending stress
of interface and allows the interfacial film sufficient flexi-
bility to take up different curvatures required to form NEs
over a wide range of composition. Thus, the co-emulsifiers
selected for the study were PG and plurol oleiuqe CC 497
(PO-497) which has HLB value of 11.6 and 6, respectively.
Pseudo ternary phase diagram
A ternary phase diagram explains the selection of the for-
mulations from the phase diagrams to avoid
metastable formulations having minimum emulsifier con-
centration, in the least possible time. The pseudo ternary
phase diagrams were constructed by varying T-80: PG and
LAB: PO-497 ratios (Km) as 1:1, 2:1 and 3:1 (Figs. 1, 2),
Fig. 1 The pseudo ternary phase diagrams of the oleic acid, tween 80: propylene glycol (Smix), water system at the 1:1 (a), 2:1 (b) and 3:1
(c) weight ratios of Smix (Km) at ambient temperature. The dark area represents nanoemulsion region
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respectively. The shaded areas of phase diagrams show the
NE regions, whereas the non-shaded area displays the
multiphase emulsion region. The area of NE isotropic
region changed slightly in size with Km in order of
3:1[ 2:1[ 1:1 for LAB:PO-497 and 1:1[ 2:1[ 3:1 for
T-80:PG, respectively. It was observed that the highest NE
area was obtained at Km-3 for LAB:PO-497 and Km-1 for
T-80: PG at 1:1, respectively. Hence, these values were
kept fixed for further studies.
Physicochemical characterization of nanoemulsion
The pH values of all the formulated NE were found within
the physiological range (5–6.5), which is one of the for-
mulation considerations that may help in reducing the
irritation produced upon instillation. Conductivity mea-
surements rely on the poor conductivity of oil compared
with water and give low values in w/o emulsions, where oil
is the continuous phase. The reverse happens for o/w
emulsion. The conductivity measurements (0.107–
0.165 mS/cm) indicate NEs to be of oil in water type. %
T values of all NE formulations were between 97 and
100 %. Hence, all the NEs were found to be optically clear.
Refractive index is the net value of the components of NE
and indicates isotropic nature of formulation. The data in
Table 2 indicate that the mean value of the refractive index
for all the formulations was approximately similar. The
results revealed that there were no interactions between NE
components and drug. Viscosity of all formulated NE
formulations was very low which is shown in Table 2. Low
viscosity values ensure easy handling, packing and hassle-
free administration of formulations (Kumar et al. 2009;
Lalani et al. 2014; Patel et al. 2013a, b).
The globule size of all formulated NEs was found below
200 nm. The results indicated that increasing the concen-
tration of Emix, resulted in improved NE clarity and a
smaller globule size. Such a decrease in globule size is the
result of more emulsifier being available to stabilize the
oil–water interface and due to the increase in emulsifier
interfacial area and decrease in interfacial tension. Fur-
thermore, the decrease in the globule size reflects the for-
mation of a better close packed film of emulsifier at the oil–
water interface, thereby stabilizing the oil globules. Poly-
dispersity index (PDI) is a measure of globule homogeneity
and it varies from 0.0 to 1.0. Polydispersity is the ratio of
standard deviation to mean globule size; hence, it indicates
the uniformity of globule size within the formulation
(Kumar et al. 2009; Lalani et al. 2014; Patel et al. 2013a,
b). The polydispersity index was found to be between
0.129 and 0.263 for formulations PNE1–PNE10 (Table 2).
Generally, an increase of electrostatic repulsive forces
between NE globules prevents the coalescence of NE
globules. On the contrary, a decrease of electrostatic
repulsive forces will cause phase separation. Zeta potential
gives certain information about the surface charge prop-
erties, and further the long-term physical stability of the
NEs. As all the excipient used were nonionic in nature, low
zeta potential values could be attributed to the drug
molecules having ionizable group (Lalani et al. 2014; Patel
et al. 2013a, b). The zeta potential values of all formula-
tions are reported in Table 2.
PALI content of NE formulations was found in the range
of 97.93–99.00 % w/w of theoretical value (5 mg/mL)
(Table 2).
The results of in vitro release study indicates that PNE6
showed highest cumulative percentage release
(85.09 ± 0.78) and PNE10 showed the lowest cumulative
percentage release value (63.33 ± 0.49) as depicted in
Table 2, and was not statistically significant (p[ 0.05).
Also it was observed that the release rate of NE formula-
tions containing LAB as emulsifier were higher as com-
pared to NE formulations containing T-80 as emulsifier
(Fig. 3). Therefore, the PNE4, PNE5, and PNE6 formula-
tions having suitable physicochemical properties and
Fig. 2 The pseudo ternary phase diagrams of the oleic acid, labrasol: plurol oleique CC 497 (Smix), water system at the 1:1 (a), 2:1 (b) and 3:1
(c) weight ratios of Smix (Km) at ambient temperature. The dark area represents nanoemulsion region
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higher drug release rate were selected as optimized for-
mulations for further studies (Patel et al. 2013a, b).
Formulation and characterization of mucoadhesive
nanoemulsion
Polycarbophil has been studied extensively as mucoadhe-
sive platform for drug delivery to the nasal mucosa (Kumar
et al. 2009; Lalani et al. 2014; Patel et al. 2013a, b) in a
concentration of 0.5 % w/w. This anionic polymer is most
widely employed mucoadhesive polymer within pharma-
ceutical formulation due to its high mucoadhesive func-
tionality and low toxicity. Polycarbophil form easily
modified networks, is a non-irritant, non-toxic and con-
sidered safe for use by FDA. Thus, polycarbophil was
selected as mucoadhesive polymer and incorporated in
optimized NE formulations (PNE4, PNE5 and PNE6) at
0.5 % w/v concentration (Barakat et al. 2006; Karasulu
et al. 2008; Kumar et al. 2009) to obtain PALI loaded
mucoadhesive NE formulations (PMNE4, PMNE5 and
PMNE6). Characterization parameters for optimized PALI
mucoadhesive NEs are shown in Table 3. All studied
muucoahesive NE formulations showed suitable physico-
chemical parameters.
Ex vivo permeation study
In ex vivo diffusion studies of PALI formulations, suc-
cessful diffusion through sheep nasal mucosa was obtained
and the results are presented in Fig. 4, and the calculated
diffusion coefficients are tabulated in Table 4 along with
the regression coefficients (r2) for first-order, Higuchi, and
zero-order modeling of the diffusion profiles for each for-
mulation (Barakat et al. 2006).
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PALI show better diffusion from PMNE6 as compared
to PMNE5, PMNE4 and PS through sheep nasal mucosa
after 4 h (p\ 0.05). The decreasing order of diffusion
coefficient for the tested formulations was PMNE4\PS\
PMNE5\PMNE6. For PMNE6, the drug exhibited
highest diffusion coefficient (2.04 9 10-5 ± 0.022 9
10-5 cm2/min) and flux (5.072 ± 0.13 lg/cm2/min) with
enhancement ratio of 1:1 as compared to PS. The
mucoadhesive NEs demonstrated higher diffusion due to
the presence of mucoadhesive agent that probably due to its
intrinsic character tends to adhere to mucosa, thereby
causing increased contact time, and hence increased dif-
fusion (Jogani et al. 2008; Kumar et al. 2008, 2009; Patel
et al. 2009, 2013a, b).
On modeling, the diffusion of drug from PALI formu-
lations demonstrated higher r2 values for the Higuchi
model as compared to zero- and first-order models. This
may be due to the fact that the diffusion system used has a
reservoir compartment (donor compartment) and sheep
mucosa acts as a barrier or controlling membrane; hence,
the diffusion process will mimic and shall be closer to
reservoir system than zero-order (concentration indepen-
dent) or first-order (concentration gradient) diffusion. Thus,
on the basis of highest diffusion coefficient, PALI loaded
PMNE6 was considered as optimized batch and further
evaluated (Jogani et al. 2008; Kumar et al. 2008, 2009;
Patel et al. 2009, 2013a, b).
Nasal cilio toxicity
The nasal cilio toxicity studies were carried out to evaluate
any potential toxic effects of excipients used in the for-
mulation on the nasal mucosa. The nasal mucosa treated
with PBS (pH 6.4, negative control) showed no sign of
inflammation, erosion and nasociliary damage (Fig. 5a),
and the nasal membrane remained intact, whereas an
extensive damage to nasal mucosa coupled with loss of
nasal cilia (Fig. 5b) could be observed with positive con-
trol. However, with PALI loaded MNE (PMNE6), damage
to nasal mucosa was not observed (Fig. 5c), which sub-
stantiated the safety of the excipients used in the formu-
lation. Therefore, formulation components can be
considered as biocompatible, and may not induce serious
histological changes in the nasal mucosa upon prolong use
Fig. 4 Cumulative amount of drug permeated per unit area versus
time profile of PS, PMNE4, PMNE5 and PMNE6













PS 5.51 ± 0.03 – – – – – 99.34 ± 0.35
PMNE4 5.61 ± 0.02 0.110 ± 0.01 124.27 ± 1.10 47.4 ± 2.11 0.210 ± 0.01 -31.3 ± 1.54 99.75 ± 0.68
PMNE5 5.68 ± 0.02 0.121 ± 0.01 119.47 ± 0.65 43.3 ± 1.24 0.143 ± 0.02 -32.9 ± 1.70 99.15 ± 0.61
PMNE6 5.97 ± 0.02 0.130 ± 0.01 116.73 ± 0.95 31.1 ± 1.44 0.178 ± 0.04 -29.7 ± 1.14 99.60 ± 0.53
a Polydispersity Index
Table 4 Steady state flux, enhancement ratio, diffusion co-efficient and modeling parameters of PALI solution (PS) and paliperidone loaded
mucoadhesive nanoemulsions (PMNE4, PMNE5 and PMNE6) (mean ± SD, n = 3)













PS 4.573 ± 0.21 1.00 1.84 9 10-5 ± 0.013 9 10-5 0.9112 0.8826 0.9805
PMNE4 3.544 ± 0.27 0.77 1.42 9 10-5 ± 0.019 9 10-5 0.9211 0.9718 0.9746
PMNE5 4.679 ± 0.50 1.03 1.89 9 10-5 ± 0.015 9 10-5 0.9329 0.9634 0.9897
PMNE6 5.072 ± 0.13 1.10 2.04 9 10-5 ± 0.022 9 10-5 0.9438 0.9387 0.9877
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(Barakat et al. 2006; Jadhav et al. 2011; Karasulu et al.
2008; Sharma et al. 2009).
Infrared study
The infrared spectra of PALI pure powder, plain NE, PNE6
and PMNE6 are as shown in the Fig. 6. PALI spectrum
shows absorption bands at 2936 and 2758.6 cm-1 due to
aliphatic C–H stretching. A prominent band at 1655 cm-1
corresponds to C=O stretching of the aryl acids and bands
at 1536.6 and 1446 cm-1 related to C=C and C=N
stretching. Bands at 1416 cm-1 are due to aliphatic C–H
bending and at 956.3, 856.5 and 817.6 cm-1 due to aro-
matic C–H bending. Other bands at 1352.2 and 1122 cm-1
corresponds to C–N stretching and C–F stretching,
respectively. The IR spectrum of PNE and PMNE is
entirely different from PALI, while it closely resembles the
spectrum of plain NE. The characteristic bands of PALI
either have disappeared or few bands of PALI reduced in
intensity probably due to the restriction inside the formu-
lation matrix. The absorption band at 3400 cm-1 due to
hydroxyl stretching was not affected in PNE and PMNE.
Five different degradation products of PALI which shows
IR absorption at 3399, 3145, 3057, 3059, 1721 cm-1 are
reported in literature. PALI and PALI loaded formulations
showed no degraded product peaks. Further, no interaction
was observed among the excipients and drug in the studied
formulations. Hence, it could be concluded that PALI was
compatible with formulation components used (Patel et al.
2013a, b, 2015).
Stability study
In stability studies, the PNE showed no evidence of pre-
cipitation of drug, creaming, phase separation, and floc-
culation on visual observation and was found to be
stable after centrifugation (30009g for 15 min) at room
temperature. The results of stability studies (Table 5)
showed that there are negligible changes in the parameters
such as drug content, % transmittance, of PALI loaded NE
and PALI loaded MNE after 6 months of storage, thus
substantiating the stability of formulation for 6 months
(Barakat et al. 2006; Jadhav et al. 2011; Karasulu et al.
2008; Sharma et al. 2009).
Conclusion
NE formulation containing PALI was successfully devel-
oped using for the purpose of improving its solubility and
transnasal delivery, which can be further utilized for its
preclinical evaluation. Screening of formulation compo-
nents helped to identify the most suitable excipients,
whereas phase diagrams gave a good idea about the con-
centrations of the formulation components that should be
used to achieve NE. Collectively, the results demonstrate
that PMNE 6, due to its appropriate physicochemical
properties, optimum emulsifier and co-emulsifier concen-
trations, highest diffusion coefficient, and free from nasal
cilio toxicity may be more suitable for intranasal delivery
Fig. 5 Photographs of sheep nasal mucosa demonstrating histolog-
ical characteristics when treated with (a) phosphate buffer saline pH
6.4 (b) isopropyl alcohol and (c) paliperidone loaded mucoadhesive
nanoemulsion
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which could be developed as a novel regime for intranasal
administration of PALI.
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